newsfilter
← Latest News
GlobeNewswire·

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

Updated Phase 2 data to be presented at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, in combination with atezolizumab in patients with metastatic microsatellite stable colorectal cancer (MSS CRC)